insulin-regulated aminopeptidase

HFI-142 is a small-molecule inhibitor that binds specifically to the active site of aminopeptidase N and suppresses its enzymatic activity. HFI-142 has been demonstrated to inhibit leukotriene A4 biosynthesis in red blood cells, an effect that may offer therapeutic potential for the research in cancer by modulating inflammatory and metabolic pathways implicated in tumor growth and progression. HFI-142 was also shown to inhibit the activity of additional aminopeptidases, including aminopeptidase N, as well as other enzymes associated with protein metabolism.

HFI-419 is a potent inhibitor of insulin-regulated aminopeptidase (IRAP) with a K i value of 0.48 μM. It is utilized in research pertaining to cognitive and memory impairments, including Alzheimer's disease, brain trauma, and stroke [1].

Aminopeptidase-IN-1 is a potent inhibitor of insulin-regulated aminopeptidase (IRAP) (Ki: 7.7 μM).Aminopeptidase-IN-1 can be used in studies of cognitive and memory disorders.

HFI-437 is a potent, non-peptidic, insulin-regulated aminopeptidase (IRAP) inhibitor with a K i of 20 nM and functions as a cognitive enhancer [1].